Controversies in autism
|Autism rights movement|
Diagnoses of autism have become more frequent since the 1980s, which has led to various controversies about both the cause of autism and the nature of the diagnoses themselves. Whether autism has mainly a genetic or developmental cause, and the degree of coincidence between autism and intellectual disability, are all matters of current scientific controversy as well as inquiry. There is also more sociopolitical debate as to whether autism should be considered a disability on its own. 
Most recent reviews of epidemiology estimate a prevalence of one to two cases per 1,000 people for autism, and about six per 1,000 for autism spectrum disorder (ASD);  because of inadequate data, these numbers may underestimate the true prevalence of ASD.  ASD averages a 4.3:1 male-to-female ratio. The number of children on the autism spectrum has increased dramatically since the 1980s, at least partly due to changes in diagnostic practice; it is unclear whether prevalence has actually increased;  and as-yet-unidentified environmental risk factors cannot be ruled out.  The risk of autism is associated with several prenatal factors, including advanced parental age and diabetes in the mother during pregnancy.  ASD is associated with several genetic disorders  and epilepsy.  Autism is also associated with intellectual disability. 
The role of genetic influence on ASD has been heavily researched over the past few years. ASD is considered to have polygenic traits since there is not a single risk factor, but multiple ones. 
Multiple twin and family studies have been conducted in order to observe any genetic influence in diagnosing ASD. The chance of both twins having ASD was significantly higher in identical twins than fraternal twins, concluding that ASD is heritable.  A reoccurring finding is that de novo (new mutation) copy number variants are a primary cause of ASD - they alter synaptic functions; germ line mutations can produce de novo CNVs.  These mutations can only be passed on to offspring; this explains the phenomenon that occurs when the child has symptoms of ASD, but the parents have no symptoms or history of ASD. De novo variants differ from person to person, i.e one variant can cause ASD in one person, whereas another person would need multiple variants to cause the same disorder.  Loss of function variants occur in 16-18% of ASD diagnoses, which is nearly double the normal population.  These loss of function variants reduce function in the protein neurexin, which connects neurons at the synapse and is important for neurological development; deletion mutations of neurexin are also very common in people with autism, as well as other neurological disorders like schizophrenia, bipolar disorder, and ADHD. 
Gut microbiome has a relation to ASD. Excessive Clostridia spp. was found in children with ASD and gastrointestinal difficulties; Clostridia spp produces propionic acid, which is impaired or in excess in people with ASD  Specifically, C. tetani and C. histolyticum are two species of this bacteria that affect people with ASD. C. tetani produces tetanus neurotoxin in the intestinal tract; C. histolyticum is a toxin producer that is abundant in people diagnosed with ASD.  Both of these could contribute to neurological symptoms.
The idea of a link between vaccines and autism was extensively investigated and shown to be false.  The scientific consensus is that there is no relationship, causal or otherwise, between vaccines and incidence of autism,    and vaccine ingredients do not cause autism. 
Nevertheless, the anti-vaccination movement continues to promote myths, conspiracy theories and misinformation linking the two.  A developing tactic appears to be the "promotion of irrelevant research [as] an active aggregation of several questionable or peripherally related research studies in an attempt to justify the science underlying a questionable claim." 
The percentage of autistic individuals who also meet criteria for intellectual disability has been reported as anywhere from 25% to 70%, a wide variation illustrating the difficulty of assessing autistic intelligence.  For pervasive developmental disorder not otherwise specified (PDD-NOS), the association with intellectual disability is much weaker.  The diagnosis of Asperger syndrome excludes clinically significant delays in mental or cognitive skills. 
A 2007 study suggested that Raven's Progressive Matrices (RPM), a test of abstract reasoning, may be a better indicator of intelligence for autistic children than the more commonly used Wechsler Intelligence Scale for Children (WISC). Researchers suspected that the WISC relied too heavily on language to be an accurate measure of intelligence for autistic individuals. Their study revealed that the neurotypical children scored similarly on both tests, but the autistic children fared far better on the RPM than on the WISC. The RPM measures abstract, general and fluid reasoning, an ability autistic individuals have been presumed to lack.  A 2008 study found a similar effect, but to a much lesser degree and only for individuals with IQs less than 85 on the Wechsler scales. 
Facilitated communication is a scientifically discredited technique  that attempts to facilitate communication by people with severe educational and communication disabilities. The facilitator holds or gently touches the disabled person's arm or hand during this process and attempts to help them move to type on a special keyboard. It was used by many hopeful parents of individuals with autism when it was first introduced during the early 1990s by Douglas Biklen, a professor at Syracuse University. 
There is widespread agreement within the scientific community and multiple disability advocacy organizations that FC is not a valid technique for authentically augmenting the communication skills of those with autism spectrum disorder.  Instead, research indicates that the facilitator is the source of the messages obtained through FC (involving ideomotor effect guidance of the arm of the patient by the facilitator).   Thus, studies have consistently found that patients are unable to provide the correct response to even simple questions when the facilitator does not know the answers to the questions (e.g., showing the patient but not the facilitator an object).  In addition, numerous cases have been reported by investigators in which disabled persons were assumed by facilitators to be typing a coherent message while the patient's eyes were closed or while they were looking away from or showing no particular interest in the letter board.  Despite the evidence opposing FC, many continue to use and promote this technique. 
Note that facilitated communication is separate and different from a range of scientifically-supported augmentative and alternative communication (AAC) devices and processes that facilitate communication for people with communication difficulties.
There are two major conceptualizations of autism within autism advocacy. Those who favour the pathology paradigm, which aligns with the medical model of disability, see autism as a disorder to be treated or cured. Those who favor the pathology paradigm argue that atypical behaviors of autistic individuals are detrimental and should therefore be reduced or eliminated through behavior modification therapies. Their advocacy efforts focus primarily on medical research to identify genetic and environmental risk factors in autism. Those who favour the neurodiversity paradigm, which aligns with the social model of disability, see autism as a naturally-occurring variation in the brain. Neurodiversity advocates argue that efforts to eliminate autism should not be compared, for example, to curing cancer, but instead to the antiquated notion of curing left-handedness. Their advocacy efforts focus primarily on acceptance, accommodation, and support for autistic people as "neuro-minorities" in society.  These two paradigms are not fully exclusive, and many people hold a combination of these viewpoints.
The pathology paradigm is the traditional view of autism through a biomedical lens, in which it is seen as a disorder characterized by various impairments, mainly in communication and social interaction.   Those taking this perspective believe that autism is generally a kind of harmful dysfunction.  Ways of functioning which diverge from a typical brain are "incorrect" or "unhealthy" and must therefore be treated or cured.  The atypical behaviors of autistic individuals are considered a detriment to social and professional success and should therefore be reduced or eliminated through therapy.  
Advocates with this view include both a small but significant minority of autistic adults and large majority of parents of autistic children, but contain a higher percentage of parents when compared to those adopting the neurodiversity paradigm.  These advocates believe that medical research is necessary to address the "autism epidemic",  reduce suffering, and provide the best outcomes for autistic individuals. In addition to etiological research, other areas of focus may include biology, diagnosis, and treatment, including medication, behavioural and psychological interventions, and the treatment of co-existing medical conditions. 
Advocacy groups that focus primarily on medical research include Autism Speaks, the Autism Science Foundation, and its predecessor organizations, the Autism Coalition for Research and Education, the National Alliance for Autism Research, and Cure Autism Now, and the former Autism Research Institute.
The neurodiversity paradigm is a view of autism as a different way of being rather than as a disease or disorder that must be cured.   Autistic people are considered to have neurocognitive differences  which give them distinct strengths and weaknesses, and are capable of succeeding when appropriately accommodated and supported.   Efforts to eliminate autism should not be compared, for example, to curing cancer but instead to the antiquated notion of curing left-handedness. 
There is no leader of the neurodiversity movement and little academic research has been conducted on it as a social phenomenon.  As such, proponents of the neurodiversity paradigm have heterogenous beliefs,  but are consistent in the view that autism cannot be separated from an autistic person.  Advocacy efforts may include opposition to therapies that aim to make children "indistinguishable from their peers,"  accommodations in schools and work environments,  and lobbying for the inclusion of autistic people when making decisions that affect them. 
Neurodiversity advocates are opposed to medical research for a cure, believing that it will lead to eugenics, and instead support research that helps autistic people thrive as they are.  For example, NeuroTribes author Steve Silberman noted a lack of research in regards to seizure-controlling drugs and autistic brains; that sensory differences in autistic people were unheard of until Temple Grandin spoke about her experiences; and that only a small percentage of research funding goes towards the needs of autistic adults.   
Advocacy groups that focus primarily on acceptance and accommodation include Autism Network International, Autism National Committee, Autistic Self Advocacy Network, and Autistic Women & Nonbinary Network.
This article has multiple issues. Please help to improve it or discuss these issues on the talk page. ( Learn how and when to remove these template messages)
Although the 2013 fifth revision of the Diagnostic and Statistical Manual of Mental Disorders ( DSM-5) has more specificity, it also has reports of more limited sensitivity. Owing to the changes to the DSM and the lessening of sensitivity, there is the possibility that individuals who were diagnosed with autistic spectrum disorders (ASD) using the fourth revision ( DSM-IV-TR) will not receive the same diagnosis with the DSM-5.
From the 933 individuals that were evaluated, 39 percent of the samples that were diagnosed with an ASD using the DSM-IV-TR criteria did not meet the DSM-5 criteria for that disorder.[ unreliable medical source?]  Essentially, the DSM-5 criteria no longer classified them with having ASD, deeming them without a diagnosis. It was likely that individuals that exhibited higher cognitive functioning and had other disorders, such as Asperger's or PDD-NOS, were completely excluded from the criteria. Also, it is more probable that younger children who do not exhibit the entirety of the symptoms and characteristics of ASD are more at risk of being excluded by the new criteria since they could have Asperger's, as Asperger's does not usually show symptoms until later in childhood. Because the onset age is different in Asperger's from autism, grouping together the disorders does not typically allow or distinguish the differentiating ages of onset, which is problematic in diagnosing. It is evident, through the various studies, that the number of people being diagnosed will be significantly diminished as well, which is prominently due to the DSM-5's new criteria. 
- Decoteau, C. L., & Daniel, M. (2020). Scientific Hegemony and the Field of Autism. American Sociological Review.
- Morgan, Jules (2016-10-01). "Autism spectrum disorder: difference or disability?". The Lancet Neurology. 15 (11): 1126. doi: 10.1016/S1474-4422(16)30002-3. ISSN 1474-4422. S2CID 54341655.
- Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, Mandell DS, Miller LA, Pinto-Martin J, Reaven J, Reynolds AM, Rice CE, Schendel D, Windham GC (2007). "The epidemiology of autism spectrum disorders". Annual Review of Public Health. 28: 235–58. doi: 10.1146/annurev.publhealth.28.021406.144007. PMID 17367287.
- Caronna EB, Milunsky JM, Tager-Flusberg H (June 2008). "Autism spectrum disorders: clinical and research frontiers". Archives of Disease in Childhood. 93 (6): 518–23. doi: 10.1136/adc.2006.115337. PMID 18305076. S2CID 18761374.
- Rutter M (January 2005). "Incidence of autism spectrum disorders: changes over time and their meaning". Acta Paediatrica. 94 (1): 2–15. doi: 10.1111/j.1651-2227.2005.tb01779.x. PMID 15858952. S2CID 79259285.
- Gardener H, Spiegelman D, Buka SL (July 2009). "Prenatal risk factors for autism: comprehensive meta-analysis". The British Journal of Psychiatry. 195 (1): 7–14. doi: 10.1192/bjp.bp.108.051672. PMC 3712619. PMID 19567888.
- Zafeiriou DI, Ververi A, Vargiami E (June 2007). "Childhood autism and associated comorbidities". Brain & Development. 29 (5): 257–72. doi: 10.1016/j.braindev.2006.09.003. PMID 17084999. S2CID 16386209.
- Levisohn PM (2007). "The autism-epilepsy connection". Epilepsia. 48 Suppl 9 (Suppl 9): 33–5. doi: 10.1111/j.1528-1167.2007.01399.x. PMID 18047599. S2CID 25651749.
- Chakrabarti S, Fombonne E (June 2001). "Pervasive developmental disorders in preschool children". JAMA. 285 (24): 3093–9. doi: 10.1001/jama.285.24.3093. PMID 11427137.
- Robinson EB, Neale BM, Hyman SE (December 2015). "Genetic research in autism spectrum disorders". Current Opinion in Pediatrics. 27 (6): 685–91. doi: 10.1097/MOP.0000000000000278. PMC 4650984. PMID 26371945.
- Bourgeron T (2016-07-01). "Current knowledge on the genetics of autism and propositions for future research". Comptes Rendus Biologies. 339 (7–8): 300–7. doi: 10.1016/j.crvi.2016.05.004. PMID 27289453.
- Ronemus M, Iossifov I, Levy D, Wigler M (February 2014). "The role of de novo mutations in the genetics of autism spectrum disorders". Nature Reviews. Genetics. 15 (2): 133–41. doi: 10.1038/nrg3585. PMID 24430941. S2CID 9073763.
- Chen J, Yu S, Fu Y, Li X (2014-09-11). "Synaptic proteins and receptors defects in autism spectrum disorders". Frontiers in Cellular Neuroscience. 8: 276. doi: 10.3389/fncel.2014.00276. PMC 4161164. PMID 25309321.
- Frye RE, Rose S, Slattery J, MacFabe DF (2015-05-07). "Gastrointestinal dysfunction in autism spectrum disorder: the role of the mitochondria and the enteric microbiome". Microbial Ecology in Health and Disease. 26: 27458. doi: 10.3402/mehd.v26.27458. PMC 4425813. PMID 25956238.
- Li Q, Han Y, Dy AB, Hagerman RJ (2017). "The Gut Microbiota and Autism Spectrum Disorders". Frontiers in Cellular Neuroscience. 11: 120. doi: 10.3389/fncel.2017.00120. PMC 5408485. PMID 28503135.
- The Editors Of The Lancet (February 2010). "Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children". Lancet. 375 (9713): 445. doi: 10.1016/S0140-6736(10)60175-4. PMID 20137807. S2CID 26364726. Lay summary – BBC News (2010-02-02).
- Taylor, Luke E.; Swerdfeger, Amy L.; Eslick, Guy D. (2014-06-17). "Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies". Vaccine. 32 (29): 3623–3629. doi: 10.1016/j.vaccine.2014.04.085. ISSN 1873-2518. PMID 24814559.
- Bonhoeffer J, Heininger U (June 2007). "Adverse events following immunization: perception and evidence" (PDF). Current Opinion in Infectious Diseases. 20 (3): 237–46. doi: 10.1097/QCO.0b013e32811ebfb0. PMID 17471032. S2CID 40669829.
- Boseley S (February 2, 2010). "Lancet retracts 'utterly false' MMR paper". The Guardian. Retrieved February 2, 2010.
- Taylor LE, Swerdfeger AL, Eslick GD (June 2014). "Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies". Vaccine. 32 (29): 3623–9. doi: 10.1016/j.vaccine.2014.04.085. PMID 24814559.
- "Vaccines Do Not Cause Autism Concerns". Centers for Disease Control and Prevention. 2018-12-12. Retrieved 2019-02-07.
- Cummins, Eleanor (February 1, 2019). "How autism myths came to fuel anti-vaccination movements". Popular Science.
- Foster, Craig A.; Ortiz, Sarenna M. (2017). "Vaccines, Autism, and the Promotion of Irrelevant Research: A Science-Pseudoscience Analysis". Skeptical Inquirer. 41 (3): 44–48. Archived from the original on 2018-10-06. Retrieved 6 October 2018.
- Dawson M, Mottron L, Gernsbacher MA (2008). "Learning in autism" (PDF). In Byrne JH (-in-chief), Roediger HL III (vol.) (ed.). Learning and Memory: A Comprehensive Reference. 2. Academic Press. pp. 759–72. doi: 10.1016/B978-012370509-9.00152-2. ISBN 978-0-12-370504-4.
- DSM-IV-TR Diagnostical and Statistical Manual of Mental Disorders Fourth edition text revision. American Psychiatric Association, Washington DC. 2000. p. 80.
- Dawson M, Soulières I, Gernsbacher MA, Mottron L (August 2007). "The level and nature of autistic intelligence". Psychological Science. 18 (8): 657–62. doi: 10.1111/j.1467-9280.2007.01954.x. PMC 4287210. PMID 17680932. Lay summary – ScienceDaily (2007-08-05).
- Bölte S, Dziobek I, Poustka F (April 2009). "Brief report: The level and nature of autistic intelligence revisited". Journal of Autism and Developmental Disorders. 39 (4): 678–82. doi: 10.1007/s10803-008-0667-2. PMID 19052857.
- Vyse, Stuart. "Autism Wars: Science Strikes Back". Skeptical Inquirer Online. Skeptical Inquirer. Retrieved 28 November 2018.
- "Institute on Communication and Inclusion". Syracuse University School of Education. Retrieved April 28, 2017.
- Hemsley, Bronwyn; Bryant, Lucy; Schlosser, Ralf; Shane, Howard; Lang, Russell; Paul, Diane; Benajee, Meher; Ireland, Marie (2018). "Systematic review of facilitated communication 2014-2018 finds no new evidence that messages delivered using facilitated communication are authored by the person with the disability". Autism and Developmental Language Impairments. 3: 1–8. doi: 10.1177/2396941518821570.
- Lilienfeld; et al. "Why debunked autism treatment fads persist". Science Daily. Emory University. Retrieved 10 November 2015.
- Ganz, Jennifer B.; Katsiyannis, Antonis; Morin, Kristi L. (February 2017). "Facilitated Communication". Intervention in School and Clinic. 54: 52–56. doi: 10.1177/1053451217692564.
- Montee, B B; Miltenberger, R G; Wittrock, D; Watkins, N; Rheinberger, A; Stackhaus, J (1995). "An experimental analysis of facilitated communication". Journal of Applied Behavior Analysis. 28 (2): 189–200. doi: 10.1901/jaba.1995.28-189. PMC 1279809. PMID 7601804.
- Goldacre, Ben (2009-12-05). "Making contact with a helping hand". The Guardian. Retrieved 10 November 2015.
- Chapman, Robert (2019). "Neurodiversity Theory and Its Discontents: Autism, Schizophrenia, and the Social Model of Disability". In Tekin, Serife; Bluhm, Robyn (eds.). The Bloomsbury Companion to Philosophy of Psychiatry. Bloomsbury Academic. pp. 371–387. ISBN 9781350024069.
- Liu, Ka-Yuet; King, Marissa; Bearman, Peter S. (March 2010). "Social influence and the autism epidemic". American Journal of Sociology. 115 (5): 1387–1434. doi: 10.1086/651448. ISSN 0002-9602. PMC 2927813. PMID 20503647.
- "What is Autism?". Autism Science Foundation. Retrieved 2019-08-03.
- Feinstein, Adam (2017-12-11). "Neurodiversity: the cases for and against" (PDF).
- "Autism Speaks releases new strategic plan for science". Autism Speaks. Retrieved 2019-08-03.
- "Strategic Plan for Science 2018-2020" (PDF). Autism Speaks. 2017-12-13.
- Solomon, Andrew (2008-05-23). "The Autism Rights Movement". New York Magazine. Retrieved 2019-08-03.
- Twachtman-Cullen D (2008). "Dr. Geraldine Dawson: setting the research agenda for Autism Speaks" (PDF). Autism Spectr Q (16): 8–11. Archived from the original (PDF) on 2009-05-30.
- Silberman, Steve (2016-04-04). "Autistic people are not failed versions of "normal." They're different, not less". ideas.ted.com. Retrieved 2019-08-03.
- Harmon, Amy (2004-12-20). "How About Not 'Curing' Us, Some Autistics Are Pleading". The New York Times. ISSN 0362-4331. Retrieved 2019-08-03.
- Nerenberg, Jenara (2016-11-21). "Does Neurodiversity Have a Future?". Greater Good Magazine. Retrieved 2019-08-03.
- "Position Statements". Autistic Self Advocacy Network. Retrieved 2019-08-03.
- Teital, Emma (2015-08-25). "Steve Silberman on autism and 'neurodiversity'". Macleans. Retrieved 2019-08-03.
- Barton ML, Robins DL, Jashar D, Brennan L, Fein D (May 2013). "Sensitivity and specificity of proposed DSM-5 criteria for autism spectrum disorder in toddlers". Journal of Autism and Developmental Disorders. 43 (5): 1184–95. doi: 10.1007/s10803-013-1817-8. PMC 3684196. PMID 23543293.